Brumfitt W, Hamilton-Miller J M
Urinary Infection Clinic, Royal Free Hospital, Hampstead, London, England.
Infection. 1987;15(5):344-7. doi: 10.1007/BF01647735.
Cephradine 250 mg at night for 12 months was given as a prophylactic measure to 33 female patients of mean age 41.6 years, who had a history in the preceding 12 months of between three and 24 (median = 7) episodes of frequency and/or dysuria. When on such treatment the mean period between symptomatic attacks was 300 days, while before treatment attacks occurred at a mean frequency of 60.3 days. Thus, prophylactic cephradine increased the interval between attacks five-fold. In a total of 9002 patient-days of treatment, only five bacteriuric breakthrough infections occurred. 27% of the patients reported adverse effects "probably" or "possibly" related to treatment. Hence, cephradine appears to be as effective and better tolerated than macrocrystalline nitrofurantoin, presently the drug of choice for the prophylaxis of recurrent urinary infections.
对33名平均年龄41.6岁的女性患者采取预防措施，每晚服用250毫克头孢拉定，为期12个月。这些患者在过去12个月中有3至24次（中位数=7次）尿频和/或排尿困难发作史。接受该治疗时，症状发作的平均间隔时间为300天，而治疗前发作的平均频率为60.3天。因此，预防性使用头孢拉定使发作间隔时间增加了五倍。在总共9002个患者治疗日中，仅发生了5例菌尿突破性感染。27%的患者报告了“可能”或“可能与”治疗相关的不良反应。因此，头孢拉定似乎与目前预防复发性尿路感染的首选药物大结晶呋喃妥因一样有效，且耐受性更好。
